Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The serine/threonine kinase mTOR is essential for the phosphoinositide 3-kinases (PI3K) signaling pathway, and regulates the development and function of immune cells. Aberrant activation of mTOR signaling pathway is associated with many cancers including leukemia. Here, we report the contributions of mTOR signaling to growth of human leukemic cell lines and mouse T-cell acute leukemia (T-ALL) cells. Torin, an ATP-competitive mTOR inhibitor, was found to have both cytotoxic and cytostatic effects on U-937, THP-1, and RPMI-8226 cells, but not on Jurkat or K-562 cells. All cells were relatively resistant to rapamycin even with suppressed activity of mTOR complex 1. Growth of T-ALL cells induced by Notch1 was profoundly affected by torin partially due to increased expression of Bcl2l11 and Bbc3. Of note, activation of Akt or knockdown of FoxO1 mitigated the effect of mTOR inhibition on T-ALL cells. Our data provide insight on the effect of mTOR inhibitors on the survival and proliferation of leukemic cells, thus further improving our understanding on cell-context-dependent impacts of mTOR signaling.
Abstract
The serine/threonine kinase mTOR is essential for the phosphoinositide 3-kinases (PI3K) signaling pathway, and regulates the development and function of immune cells. Aberrant activation of mTOR signaling pathway is associated with many cancers including leukemia. Here, we report the contributions of mTOR signaling to growth of human leukemic cell lines and mouse T-cell acute leukemia (T-ALL) cells. Torin, an ATP-competitive mTOR inhibitor, was found to have both cytotoxic and cytostatic effects on U-937, THP-1, and RPMI-8226 cells, but not on Jurkat or K-562 cells. All cells were relatively resistant to rapamycin even with suppressed activity of mTOR complex 1. Growth of T-ALL cells induced by Notch1 was profoundly affected by torin partially due to increased expression of Bcl2l11 and Bbc3. Of note, activation of Akt or knockdown of FoxO1 mitigated the effect of mTOR inhibition on T-ALL cells. Our data provide insight on the effect of mTOR inhibitors on the survival and proliferation of leukemic cells, thus further improving our understanding on cell-context-dependent impacts of mTOR signaling.
참고문헌 (23)
- Powell JD, "Regulation of immune responses by mTOR", Annu Rev Immunol, 30, pp.39~68 (2012)
- Laplante M, "mTOR signaling in growth control, disease", Cell, 149, pp.274~293 (2012)
- Zeng H, "mTOR, lymphocyte metabolism", Curr Opin Immunol, 25, pp.347~355 (2013)
- Lee K, "Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1, Th2 cell subsets via distinct signaling pathways", Immunity, 32, pp.743~753 (2010)
- Lee K, "Requirement for Rictor in homeostasis, function of mature B lymphoid cells", Blood, 122, pp.2369~2379 (2013)
- Lee K, "Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation, leukemia", J Exp Med, 209, pp.713~728 (2012)
- Weichhart T, "Regulation of innate immune cell function by mTOR", Nat Rev Immunol, 15, pp.599~614 (2015)
- Hoshii T, "Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis, eradicates T-cell acute lymphoblastic leukemia cells", Proc Natl Acad Sci U S A, 111, pp.3805~3810 (2014)
- Engelman JA, "Targeting PI3K signalling in cancer:opportunities, challenges, limitations", Nat Rev Cancer, 9, pp.550~562 (2009)
- Bertacchini J, "Targeting PI3K", AKT, Cell Mol Life Sci, pp.2015, 72[DOI]
- Tamburini J, "Constitutive phosphoinositide 3-kinase", Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients, 2007, pp.110, 1025~1028
- Silva A, "PTEN posttranslational inactivation, hyperactivation of the PI3K", Akt pathway sustain primary T cell leukemia viability, 2008, pp.118, 3762~3774
- Magee JA, "Temporal changes in PTEN, mTORC2 regulation of hematopoietic stem cell self-renewal, leukemia suppression", Cell Stem Cell, 11, pp.415~428 (2012)
- Kalaitzidis D, "mTOR complex 1 plays critical roles in hematopoiesis, Pten-lossevoked leukemogenesis", Cell Stem Cell, 11, pp.429~439 (2012)
- Xu Q, "mTOR regulates cell survival after etoposide treatment in primary AML cells", Blood, 106, pp.4261~4268 (2005)
- Simioni C, "Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia, its therapeutic potential to prevent Akt reactivation", Oncotarget, 5, pp.10034~10047 (2014)
- Wan X, "Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism", Oncogene, 26, pp.1932~1940 (2007)
- Feldman ME, "Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1, mTORC2", PLoS Biol, 7, pp.e38~ (2009)
- Sarbassov DD, "Prolonged rapamycin treatment inhibits mTORC2 assembly, Akt", PKB, 2006, pp.22, 159~168
- Badura S, "Differential effects of selective inhibitors targeting the PI3K", AKT, PLoS One, pp.2013, 8[DOI]
- Dan HC, "Akt-dependent regulation of NF-{kappa}B is controlled by mTOR, Raptor in association with IKK", Genes Dev, 22, pp.1490~1500 (2008)
- Wang P, "PUMA is directly activated by NF-kappaB, contributes to TNF-alpha-induced apoptosis", Cell Death Differ, 16, pp.1192~1202 (2009)
- Brunet A, "Akt promotes cell survival by phosphorylating, inhibiting a Forkhead transcription factor", Cell, 96, pp.857~868 (1999)